ENDRA Life Sciences Inc.
NDRA · XNASCIK 1681682fmd_101S27YDDE00DG2DGXKJGHC0A8Manufacturing · Electromedical & Electrotherapeutic ApparatusTemplate: Standard
Coverage: Jan 01, 2016 to Jun 30, 2026, 42 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 0 | 0 | 0 | 0 | – | – | – | – | – |
| Cost of revenue | – | 0 | 0 | 0 | 0 | – | – | – | – | – |
| Gross profit | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – |
| Research and development | 0 | 2 | 5 | 7 | 6 | 5 | 7 | 5 | 3 | 2 |
| Selling, general and administrative | 2 | 3 | 4 | 4 | 6 | 6 | 7 | 6 | 8 | 4 |
| Total operating expenses | 2 | 5 | 9 | 11 | 12 | 11 | 13 | 11 | 11 | 6 |
| Operating income | (2) | (5) | (9) | (11) | (12) | (11) | (13) | (11) | (11) | (6) |
| Interest expense | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Other non-operating income (expense) | – | (1) | (1) | (2) | (0) | 0 | (0) | 0 | (1) | (1) |
| Income before taxes | (3) | (5) | (10) | (13) | (12) | (11) | (13) | (10) | (12) | (7) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Net income from continuing operations | (3) | (5) | (10) | (13) | (12) | (11) | (13) | (10) | (12) | – |
| Net income | (3) | (5) | (10) | (13) | (12) | (11) | (13) | (10) | (12) | (7) |
| Net income to common shareholders | – | – | (10) | (18) | (12) | (11) | (13) | – | – | – |